Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2022 | Prognostic markers in MCL and the value of CAR-T therapy in treating high-risk disease

Toby Eyre, MBChB (Hons), DipMedEd, MRCP (UK), FRCPath (UK), MD, Oxford University Hospitals NHS Foundation Trust, Oxford, UK, discusses prognostic markers and high-risk features in mantle cell lymphoma (MCL), including p53 mutation, high-Ki 67, and blastoid morphology. Dr Eyre also comments on the importance of planning treatment with CAR-T therapy in advance for patients with high-risk disease, and the promising responses obtained with the use of CAR-T therapy. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.


Roche: Education Honorarium, Advisory Board Honorarium, Travel to scientific conferences
Gilead: Honorarium; Research support; Travel to scientific conferences
KITE: Education Honorarium, Advisory Board Honorarium,
Janssen: Honorarium
Abbvie: Honorarium; Travel to scientific conferences
AstraZeneca: Honorarium, Research funding, Travel to scientific conferences
Loxo Oncology: Advisory Board Honorarium, Trial steering committee
Beigene: Advisory Board Honorarium, Research funding
Incyte: Advisory Board Honorarium
Secura Bio: Advisory Board Honorarium